ABSTRACT
BACKGROUND: Coronary computed tomography angiography (coronary CTA) provides non-invasive evaluation of the coronary arteries with high precision for the detection of significant coronary artery disease (CAD). AIM: To investigate whether irregular heart rhythm including atrial fibrillation and premature beats during data acquisition influences (i) radiation and contrast media exposure, (ii) number of non-evaluable coronary segments and (iii) diagnostic impact of coronary CTA. METHODS: Twelve tertiary care centers with ≥64 slice CT scanners and ≥5 years of experience with cardiovascular imaging participated in this registry. Between 2009 and 2014, 4339 examinations were analysed in patients who underwent clinically indicated coronary CTA for suspected CAD. Clinical and epidemiologic data were gathered from all patients. In addition, clinical presentation, heart rate and rhythm during the scan, Agatston score, radiation and contrast media exposure and the diagnostic impact of coronary CTA were systematically analysed. RESULTS: Of 4339 patients in total, 260 (6.0%) had irregular heart rhythm, whereas the remaining 4079 (94.0%) had stable sinus rhythm. Patients with irregular heart rhythm were older (63.2 ± 12.5yrs versus 58.6 ± 11.4yrs. p < 0.001), exhibited a higher rate of pathologic stress tests before CTA (37.1% versus 26.1%, p < 0.01) and higher heart rates during CTA compared to those with sinus rhythm (62.5 ± 11.6bpm versus 58.9 ± 8.5bpm, p < 0.001). Both contrast media exposure and radiation exposure were significantly higher in patients with irregular heart rhythm (90 mL (95%CI = 80-110 mL) versus 80 mL (95%CI = 70-90 mL) and 6.2 mSv (95%CI = 2.5-11.7) versus 3.3 mSv (95%CI = 1.7-6.9), p < 0.001 for both). Coronary CTA excluded significant CAD less frequently in patients with irregular heart rhythm (32.9% versus 44.8%, p < 0.001). This was attributed to the higher rate of examinations with at least one non-diagnostic coronary segment in patients with irregular heart rhythm (10.8% versus 4.6%, p < 0.001). Subsequent invasive angiography could be avoided in 47.2% of patients with irregular heart rhythm compared to 52.9% of patients with sinus rhythm (p = NS), whereas downstream stress testing was recommended in 3.2% of patients with irregular heart rhythm versus 4.0% of patients with sinus rhythm (p = NS). CONCLUSION: A significant number of patients scheduled for coronary CTA have irregular heart rhythm in a real-world clinical setting. In such patients, heart rate during coronary CTA is higher, possibly resulting in (i) higher radiation and contrast agent exposure and (ii) more frequent coronary CTA examinations with at least one non-diagnostic coronary artery segment. However, this does not seem to lead to increased downstream stress testing or subsequent invasive procedures.
Subject(s)
Atrial Fibrillation/physiopathology , Cardiac Complexes, Premature/physiopathology , Computed Tomography Angiography , Coronary Angiography/methods , Coronary Artery Disease/diagnostic imaging , Coronary Vessels/diagnostic imaging , Heart Rate , Multidetector Computed Tomography , Radiation Dosage , Radiation Exposure , Aged , Atrial Fibrillation/diagnosis , Atrial Fibrillation/epidemiology , Cardiac Complexes, Premature/diagnosis , Cardiac Complexes, Premature/epidemiology , Contrast Media/administration & dosage , Coronary Artery Disease/epidemiology , Coronary Artery Disease/physiopathology , Female , Germany/epidemiology , Humans , Male , Middle Aged , Predictive Value of Tests , Registries , Reproducibility of ResultsABSTRACT
AIMS: A major proportion of patients with diabetic foot syndrome are older than 65 years. Little is known about outcomes of these elderly patients. METHODS: We analysed 245 treatment cases in an observational single-centre study for comorbidities and outcomes over a 6-month period. RESULTS: In all, 122 patients had peripheral arterial disease which was significantly increasing with age (n = 245, df = 1, χ2 = 23.06, p ⩽ 0.0001). Increasing age correlated positively with decreasing rate of revascularisations (n = 122, df = 1, χ2 = 4.23, p = 0.039). In total, 23 (9.3%) patients died in the observation period. In-hospital mortality was 2.8%, percentage of major amputations 2.8%. In the invasively treated subgroup, 13 out of 67 patients died within the observation period. Death after revascularisation was independent of age (n = 67, df = 1, χ2 = 2.05, p = 0.153). Mobility decreased in the whole study group with increasing age. The risk of decrease with age was not influenced by revascularisation status. CONCLUSION: With careful interdisciplinary evaluation, elderly patients with diabetic foot syndrome can be treated with favourable outcome. Mobility before and after treatment deserves more attention as a predictor of treatment success and outcome parameter.
Subject(s)
Amputation, Surgical , Diabetic Foot/therapy , Endovascular Procedures , Mobility Limitation , Quality of Life , Vascular Surgical Procedures , Wound Healing , Adult , Age Factors , Aged , Aged, 80 and over , Amputation, Surgical/adverse effects , Amputation, Surgical/mortality , Comorbidity , Diabetic Foot/diagnosis , Diabetic Foot/mortality , Diabetic Foot/physiopathology , Endovascular Procedures/adverse effects , Endovascular Procedures/mortality , Female , Germany , Hospital Mortality , Humans , Limb Salvage , Male , Middle Aged , Patient Care Team , Recovery of Function , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Vascular Surgical Procedures/adverse effects , Vascular Surgical Procedures/mortalityABSTRACT
BACKGROUND: Third-generation drug-eluting metal stents are the gold standard for treatment of coronary artery disease. The permanent metallic caging of the vessel, however, can result in limited vasomotion, chronic inflammation, and late expansive remodeling, conditions that can lead to late and very late stent thrombosis. The development of bioresorbable scaffolds (BRSs) promises advantages over metal stents due to complete biodegradation within 2-4years. Theoretically, since vessel scaffolding is temporary and no permanent implant remains in the vessel, BRSs, as opposed to metal stents, once degraded would no longer be potential triggers for stent-related adverse events or side effects. METHODS/DESIGN: The short- and long-term outcome after implantation of an everolimus-eluting, poly-L-lactic acid-based bioresorbable scaffold system (ABSORB, Abbott Vascular, Santa Clara, CA, USA) in the world-wide greatest all-comers cohort will be evaluated in the prospective, non-interventional, multicenter German-Austrian ABSORB RegIstRy (GABI-R). GABI-R will include over 5000 patients from about 100 study sites in Austria and Germany. Safety endpoints such as cardiac death, myocardial infarction, and clinically driven percutaneous or surgical target lesion and vessel revascularization will be evaluated during hospitalization and in the follow-up period (minimum of 5years). CONCLUSION: Although two randomized controlled trials and several registries have documented safety and efficacy as well as non-inferiority of this everolimus-eluting ABSORB device compared with drug-eluting metal stents, the current knowledge regarding clinical application, treatment success, and long-term safety of using this BRS in daily routine is limited. Thus, the goal of GABI-R is to address this lack of information.
Subject(s)
Absorbable Implants , Coronary Stenosis/surgery , Drug-Eluting Stents , Everolimus/therapeutic use , Registries , Research Design , Austria , Cohort Studies , Everolimus/administration & dosage , Germany , Humans , Prospective Studies , Treatment OutcomeABSTRACT
AIMS: The aim of this post hoc subgroup analysis of the Intraaortic Balloon Pump in Cardiogenic Shock II trial was to compare the clinical outcome of patients treated with either clopidogrel or the newer, more potent P2Y12 receptor inhibitors prasugrel or ticagrelor. METHODS AND RESULTS: The primary endpoint was one-year mortality with respect to different P2Y12 receptor inhibitors. Secondary safety endpoints were GUSTO bleedings until hospital discharge. After exclusion of 117 patients (patients who died before or during PCI, patients with unavailable information on P2Y12 receptor inhibitor treatment, patients not receiving or receiving a combination of different P2Y12 receptor inhibitors as acute antiplatelet therapy), 483 patients were analysed. Of these, 373 patients (77.2%) received clopidogrel and 110 patients (22.8%) either prasugrel or ticagrelor as acute antiplatelet therapy. The adjusted rate of mortality did not differ between prasugrel/ticagrelor and clopidogrel treated patients (HR: 0.83, 95% CI: 0.59-1.19, padj=0.31). GUSTO bleedings did not differ between groups (14.3% for prasugrel/ticagrelor and 16.4% for clopidogrel, HR: 0.91, 95% CI: 0.55-1.5, padj=0.7). CONCLUSIONS: This IABP-SHOCK II trial subgroup analysis shows that the use of potent P2Y12 receptor inhibitors like prasugrel or ticagrelor is feasible and might not be harmful in selected patients with cardiogenic shock complicating acute myocardial infarction. However, the superiority in comparison to clopidogrel remains to be proven.
Subject(s)
Myocardial Infarction/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Purinergic P2Y Receptor Antagonists/therapeutic use , Shock, Cardiogenic/drug therapy , Ticlopidine/analogs & derivatives , Adult , Aged , Aged, 80 and over , Blood Platelets/drug effects , Clopidogrel , Female , Humans , Male , Middle Aged , Myocardial Infarction/complications , Myocardial Infarction/therapy , Percutaneous Coronary Intervention/methods , Purinergic P2Y Receptor Antagonists/administration & dosage , Shock, Cardiogenic/etiology , Shock, Cardiogenic/therapy , Thiophenes/administration & dosage , Thiophenes/therapeutic use , Ticlopidine/therapeutic useABSTRACT
BACKGROUND: Anticoagulation using vitamin K antagonists (VKAs) significantly reduces the risk of recurrent stroke in stroke patients with atrial fibrillation (AF) and is recommended by guidelines. METHODS: The German Competence NETwork on Atrial Fibrillation established a nationwide prospective registry including 9,574 AF patients, providing the opportunity to analyse AF management according to German healthcare providers. RESULTS: On enrolment, 896 (9.4 %) patients reported a prior ischaemic stroke or transient ischaemic attack. Stroke patients were significantly older, more likely to be female, had a higher rate of cardiovascular risk factors, and more frequently received anticoagulation (almost exclusively VKA) than patients without prior stroke history. Following enrolment, 76.4 % of all stroke patients without VKA contraindications received anticoagulation, which inversely associated with age (OR 0.95 per year; 95 % CI 0.92-0.97). General practitioners/internists (OR 0.40; 95 % CI 0.21-0.77) and physicians working in regional hospitals (OR 0.47; 95 % CI 0.29-0.77) prescribed anticoagulation for secondary stroke prevention less frequently than physicians working at university hospitals (reference) and office-based cardiologists (OR 1.40; 95 % CI 0.76-2.60). The impact of the treating healthcare provider was less evident in registry patients without prior stroke. CONCLUSIONS: In the AFNET registry, anticoagulation for secondary stroke prevention was prescribed in roughly three-quarters of AF patients, a significantly higher rate than in primary prevention. We identified two factors associated with withholding oral anticoagulation in stroke survivors, namely higher age and-most prominently-treatment by a general practitioner/internist or physicians working at regional hospitals.
Subject(s)
Anticoagulants/therapeutic use , Atrial Fibrillation/drug therapy , Guideline Adherence/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Registries , Secondary Prevention/statistics & numerical data , Stroke/prevention & control , Vitamin K/antagonists & inhibitors , Warfarin/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Atrial Fibrillation/complications , Cardiology/statistics & numerical data , Female , General Practitioners/statistics & numerical data , Germany , Hospitals , Hospitals, University/statistics & numerical data , Humans , Internal Medicine/statistics & numerical data , Ischemic Attack, Transient/etiology , Ischemic Attack, Transient/prevention & control , Male , Middle Aged , Practice Guidelines as Topic , Prospective Studies , Risk Factors , Stroke/etiology , Survivors , Young AdultABSTRACT
Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality but there are few studies available about atrial fibrillation, the most frequent arrhythmia in CKD, and the applied treatment. Based on the prospective German Competence NETwork on Atrial Fibrillation, data of 3138 patients with atrial fibrillation were analyzed and categorized by their estimated glomerular filtration rate (stages 1-3 and 4 plus 5). With advanced CKD, significantly more patients suffered from a more severe form of atrial fibrillation. Despite significantly higher CHADS2 scores in advanced CKD, oral anticoagulation was not prescribed more frequently while antiarrhythmic drugs and catheter ablations were used significantly less often, in contrast to more pacemaker implantations. However, in multivariate hierarchical logistic regression analyses of in-hospital treatments and complications, only hemorrhages and pacemaker implantations turned out to be independently and significantly associated with higher CKD stages. This nationwide study shows that patients with CKD and atrial fibrillation suffer from a markedly higher comorbidity. Thus, while CKD patients have received cardioversions, ablations, antiarrhythmic, or anticoagulation drugs significantly less often in their history, current treatments were not different if adjusted for multiple comorbidities. This might indicate an improvement in the often reported therapeutic nihilism in CKD.
Subject(s)
Atrial Fibrillation/complications , Atrial Fibrillation/therapy , Renal Insufficiency, Chronic/complications , Aged , Female , Humans , Male , Middle AgedABSTRACT
AIMS: Despite its high clinical relevance, few studies have investigated depression in patients with atrial fibrillation (AF). We aimed to assess whether depressed mood was more common in persistent or paroxysmal AF patients in controlled models and report frequencies of major depressive disorder. METHODS AND RESULTS: Cross-sectional data from two contemporary clinical trials were used to compare paroxysmal (n = 310) and persistent (n = 392) AF patients' depressed mood severity (measured by the Major Depression Inventory) with each trial including only one patient type. A four-category outcome of depressed mood severity was chosen as exposure variable. Ordinal logistic regression was applied to analyse the association of AF type with depressed mood in a crude model and a confounder control model. In the study sample, 8.4% were classified as having major depressive disorder [10.5% of persistent and 5.8% of paroxysmal patients; odds ratio (OR) = 1.89; 95% confidence interval (CI): 1.07-3.37], according to the diagnostic and statistical manual of mental disorders [(diagnostic and statistical manual of mental disorders (DSM-IV)] criteria. In both the age and sex adjusted crude model and in the confounder control model, the association of persistent AF with more severe depressed mood was significant (OR confounder controlled model = 1.44; 95% CI: 1.13-1.75, P = 0.007). CONCLUSION: Persistent AF patients may suffer from more severe depressed mood than paroxysmal AF patients with similar symptom burden after controlling for relevant factors.
Subject(s)
Atrial Fibrillation/epidemiology , Atrial Fibrillation/psychology , Clinical Trials as Topic , Depression/epidemiology , Depression/psychology , Depressive Disorder, Major/epidemiology , Depressive Disorder, Major/psychology , Aged , Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/drug therapy , Causality , Chronic Disease , Comorbidity , Cross-Sectional Studies , Depression/drug therapy , Depressive Disorder, Major/therapy , Evidence-Based Medicine , Female , Germany/epidemiology , Humans , Incidence , Male , Middle Aged , Risk Factors , Treatment OutcomeABSTRACT
BACKGROUND: Assessing health status is fundamental when weighing treatment options for atrial fibrillation (AF) patients. Most health-related quality-of-life (HRQoL) data stem from self-ratings, whereas treatment decisions are based upon physicians' estimations. METHODS: The degree of congruence between patients' and physicians' assessments of the patients' subjective health status was used as an indicator of good communication and shared understanding. A total of 334 patients with paroxysmal AF without significant concomitant heart diseases and their physicians were asked in a prospective blinded study to rate the patients' HRQoL. The Short Form-12 was used for self-ratings; the Short Form-8, for physician ratings. Using baseline data, intraclass correlations and Bland-Altman graphs were used to assess concordance; cross-sectional multivariate regression analyses assessed patient characteristics associated with discordance. RESULTS: On average, physicians rated their patients' HRQoL higher than patients did (∆mental component score [MCS] = -3.23, P < .0001, and ∆physical component score [PCS] = -2.21, P = .0001). Intraclass correlations and Bland-Altman graphs showed unsatisfactory concordance. Physical inactivity (∆ = 4.84) had the greatest bivariate effect on PCS discordance, and major depressive disorder (∆ = 7.01), on MCS discordance. In the regression analyses, depression was significantly associated with discord in the MCS (ß = -0.94, P < .001) and the PCS (ß = -0.37, P < .002). Sleeping disorder was associated with discord in the MCS (ß = -4.13, P < .002), and physical inactivity, with discord in the PCS (ß = -1.47, P = .006). CONCLUSIONS: In patients with AF, even in the absence of significant concomitant cardiac diseases, depression, followed by sleeping disorder and physical inactivity, was significantly associated with discordance. These findings should be considered by physicians when choosing treatment strategies.
Subject(s)
Angiotensin Receptor Antagonists/therapeutic use , Atrial Fibrillation/drug therapy , Health Status , Physician-Patient Relations , Quality of Life , Adolescent , Adult , Aged , Depression/epidemiology , Female , Germany , Humans , Male , Middle Aged , Patients/psychology , Physicians/psychology , Prospective Studies , Receptors, Angiotensin/metabolism , Surveys and Questionnaires , Young AdultABSTRACT
BACKGROUND: We aimed to assess whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of cardiovascular (CV) events in stable patients with established atherothrombosis or multiple risk factors. METHODS: We analysed the 23,728 European patients of the REACH Registry; 20,588 (86.8%) had established atherothrombotic disease and 3140 (13.2%) had multiple risk factors only. Aspirin (ASA) and/or NSAIDs use was determined at enrolment and ischemic events were recorded over two years of follow-up. cMACCE was defined as the composite of CV death, MI or stroke. Bleeding was defined as any bleeding leading to both hospitalisation and transfusion. RESULTS: The mean age of population was 67.2±9.8years. At baseline, 1573 patients (6.6%) received NSAIDs and 15,395 (64.9%) received ASA. Four groups were defined: 1) no ASA/no NSAIDs, 2) ASA only, 3) NSAIDs only, 4) NSAIDs+ASA, with 7722 (32.5%), 14,433 (60.8%), 611 (2.6%) and 962 (4.1%) patients in these groups, respectively. Among the 22,028 (92.8%) with complete 2-year follow-up, 683 (3.2%) died from CV causes, while 395 (1.9%) had MI, 665 (3.1%) stroke, 1651 (7.6%) cMACCE and 199 (1.0%) bleeding. After adjustment, NSAID use was independently associated with an increased risk of stroke (OR 1.635; 95% CI 1.239-2.159, p<0.001), and a trend towards an increased bleeding rate (OR 1.554; CI 95% 0.960-2.51, p=0.07). No association was found between NSAID use and MI or MACCE. CONCLUSIONS: In stable atherothrombosis patients, the use of NSAIDs appears to be independently associated with an increased cerebrovascular event risk.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Cerebrovascular Disorders/chemically induced , Cerebrovascular Disorders/epidemiology , Coronary Thrombosis/drug therapy , Coronary Thrombosis/epidemiology , Registries , Aged , Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Cerebrovascular Disorders/diagnosis , Female , Humans , Male , Middle Aged , Risk Factors , Stroke/chemically induced , Stroke/diagnosis , Stroke/epidemiology , Treatment OutcomeABSTRACT
Differential allocation (DA)-the adjustment of an individual's parental investment in relation to its mate's attractiveness-is increasingly recognized as an important component of sexual selection. However, although DA is expected by both sexes of parents in species with biparental care, DA by males has rarely been investigated. We have previously demonstrated a decrease in the feeding rates of female blue tits Cyanistes caeruleus when their mate's UV coloration was experimentally reduced (i.e. positive DA). In this study, we used the same experimental protocol in the same population to investigate DA by male blue tits in relation to their female's UV coloration. Males mated to UV-reduced females had higher feeding rates than those mated to control females (i.e. negative DA). Thus, male and female blue tits display opposite DA for the same component of parental effort (chick provisioning), the first time that this has been reported for any species.
Subject(s)
Feeding Behavior , Pigmentation , Reproduction , Songbirds/physiology , Animals , Female , Male , Mating Preference, Animal , Netherlands , Sex Characteristics , Sex Factors , Ultraviolet Rays , Visual PerceptionABSTRACT
AIMS: The European CRT Survey is a joint initiative of the Heart Failure Association (HFA) and the European Heart Rhythm Association (EHRA) of the European Society of Cardiology evaluating the contemporary implantation practice of cardiac resynchronization therapy (CRT) in Europe. METHODS AND RESULTS: Patients who had a successful CRT implantation were enrolled from 141 centres in 13 countries between November 2008 and June 2009. Baseline demographics, clinical and implantation data were collected, with a follow-up of â¼1 year (9-15 months). The current report describes clinical outcomes including symptom severity, cardiovascular (CV) hospitalization, and survival. A total of 2438 patients were enrolled, and follow-up data were acquired from 2111 patients (87%). The population included important groups of patients poorly represented in randomized controlled trials, including very elderly patients and those with prior device implantation, atrial fibrillation, and/or QRS duration <120 ms. Investigators reported substantial improvement in New York Heart Association (NYHA) functional class at follow-up. Patient self-assessment indicated that 81% of the patients felt improved, 16% reported no change, and 4% reported deterioration. During follow-up, 207 (10%) patients died, 346 (16%) had a CV hospitalization, and 501 (24%) died or had CV hospitalization. Worse NYHA functional class, atrial fibrillation, ischaemic aetiology, and device type (CRT-P, i.e. CRT alone) were associated with poorer survival. Women had a better outcome, as did patients who had a CRT-D (with an implantable cardioverter defibrillator function) device. CONCLUSIONS: Outcomes including death and hospitalization in this European CRT survey were consistent with results from clinical trials of CRT. At 1 year follow-up, most patients who received a CRT device considered their symptoms improved compared with their pre-implant assessment. Although prospective, this is an observational study of successful CRT implantations, and outcomes in subgroup analyses must be interpreted with appropriate conservatism.
Subject(s)
Atrial Fibrillation , Cardiac Resynchronization Therapy , Heart Failure , Aged , Atrial Fibrillation/complications , Atrial Fibrillation/diagnosis , Atrial Fibrillation/therapy , Cardiac Resynchronization Therapy/methods , Cardiac Resynchronization Therapy/mortality , Cardiac Resynchronization Therapy/statistics & numerical data , Cardiac Resynchronization Therapy Devices/statistics & numerical data , Data Collection , Europe , Female , Follow-Up Studies , Heart Failure/complications , Heart Failure/diagnosis , Heart Failure/therapy , Heart Function Tests/methods , Hospitalization , Humans , Male , Middle Aged , Multicenter Studies as Topic , Outcome and Process Assessment, Health Care , Randomized Controlled Trials as Topic , Risk Assessment/methods , Risk Assessment/statistics & numerical data , Risk Factors , Severity of Illness Index , Survival Analysis , Treatment OutcomeABSTRACT
AIMS: Cardiac resynchronization therapy (CRT) is an effective treatment for a subset of patients with chronic heart failure. Data on the benefit of CRT in heart failure patients with previous right ventricular pacemakers or standard defibrillators are sparse. METHODS AND RESULTS: The European (HFA, Heart Failure Association/EHRA, European Heart Rhythm Association) CRT Survey enrolled patients from 141 centres in 13 countries in Europe collecting baseline demographic, echocardiographic, clinical, and implant data, with follow-up at â¼1 year. The present analysis reports implantation data and 1 year outcomes regarding New York Heart Association (NYHA) class, global patient assessment, hospitalizations, complications, and mortality in patients undergoing de novo CRT implantations compared with those receiving an upgrade of a previously implanted device (pacemaker or implantable cardioverter-defibrillators). This analysis includes 2367 CRT implant procedures of which 692 (28%) were upgrades to CRT. Distribution of NYHA functional class and left ventricular function were similar between the groups. Procedural duration was also similar, although fluoroscopy time was shorter in the 'upgrades'. There was no difference in the frequency of peri-procedural complications. There were similar improvements in NYHA functional class and similar reduction in QRS duration, but more patients reported unchanged global assessment status in the upgraded group. Total and cause-specific mortality at 1 year was low and the same in both groups. CONCLUSIONS: More than one quarter of all CRT procedures are upgrades from existing systems, although this group has not been subject to randomized clinical trials. Our data suggest that there are no significant differences in clinical outcomes or complication rates between upgrades and de novo procedures. Clinical study no NCT 01185392.
Subject(s)
Cardiac Resynchronization Therapy , Defibrillators, Implantable , Heart Failure/mortality , Heart Failure/therapy , Aged , Aged, 80 and over , Europe/epidemiology , Female , Heart Failure/physiopathology , Humans , Male , Middle Aged , Severity of Illness Index , Treatment OutcomeABSTRACT
OBJECTIVES: To examine the impact of cardiovascular risk factor control on 3-year cardiovascular event rates in patients with stable symptomatic atherothrombotic disease in Europe. METHODS: The REduction of Atherothrombosis for Continued Health (REACH) Registry recruited patients aged ≥45 years with established atherothrombotic disease or three or more risk factors, of whom 20 588 symptomatic patients from 18 European countries were analysed in this study at baseline and 12, 24 and 36 months. 'Good control' of cardiovascular risk factors was defined as three to five risk factors at target values of international guideline recommendations (systolic blood pressure <140 mm Hg, diastolic blood pressure <90 mm Hg, fasting glycaemia <110 mg/dl, total cholesterol <200 mg/dl, non-smoking). Independent predictors of 'good control' of major risk factors were assessed by multivariate analysis. RESULTS: Among symptomatic patients in the REACH Registry Europe (mean age 67 years, 70.6% male), 59.4% had good control of risk factors at baseline. Good risk factor control was associated with lower cardiovascular death/non-fatal stroke/non-fatal myocardial infarction (OR 0.76; 95% CI 0.69 to 0.83) and mortality (OR 0.89; 95% CI 0.79 to 0.99) at 36 months, compared with poor control. Independent predictors of good control of risk factors included residence in western versus eastern Europe (OR 1.29), high level of education (OR 1.16), established coronary artery disease (OR 1.18), treatment with one or more antithrombotic (OR 1.59) and one or more lipid-lowering agent (OR 1.16). CONCLUSIONS: In REACH, less than 60% of patients with stable atherothrombotic disease had good control of the five major cardiovascular risk factors. Improved risk factor control is associated with a positive impact on 3-year cardiovascular event rates and mortality.
Subject(s)
Atherosclerosis/therapy , Cardiovascular Diseases/prevention & control , Guideline Adherence , Registries , Thrombosis/therapy , Aged , Atherosclerosis/complications , Atherosclerosis/epidemiology , Cardiovascular Diseases/epidemiology , Epidemiologic Methods , Europe/epidemiology , Female , Humans , Male , Middle Aged , Practice Guidelines as Topic , Risk Reduction Behavior , Thrombosis/complications , Thrombosis/epidemiologyABSTRACT
BACKGROUND: Although guidelines recommend similar evaluation and treatment for both sexes, differences in approach and outcomes have been reported. DESIGN: Prospective, observational registry. METHODS: Consecutive patients at high cardiovascular risk were assessed for risk factors and management at baseline,and followed-up for 2 years. RESULTS: Twenty-two thousand and twenty-eight patients with documented arterial disease (symptomatic) or three or more atherothrombotic risk factors (asymptomatic) completed the 2-year follow-up of the REduction of Atherothrombosis for Continued Health Registry in Europe (women, 31.5%; men, 68.4%). Women patients were 3.3 years (mean) older than men. Few differences were observed between asymptomatic men and women in risk factor profile or management at baseline. Higher proportions of symptomatic women than men had diabetes (P<0.001), hypertension (P<0.0001), elevated total cholesterol levels (P<0.0001) or elevated triglycerides (P<0.01). A much lower proportion of women than men were current smokers (asymptomatic, 14.6 vs. 29.3%; symptomatic, 11.9 vs.19.5%, both P<0.0001). Within the symptomatic population, women received antithrombotic agents (91.8 vs. 94.9%,P<0.0001) and lipid-lowering agents (68.2 vs. 73.1%, P<0.0001) less frequently than men. After multivariate adjustment,fewer symptomatic women than men had undergone coronary revascularizations at 2 years (odds ratio, 0.72; 95% confidence interval, 0.61-0.85). There were no differences in primary outcomes, including cardiovascular death/myocardial infarction/stroke (odds ratio, 1.01, 95% confidence interval, 0.93-1.11, P=0.78), between the sexes. DISCUSSION: Although no differences were found in cardiovascular event rates at 2-year follow-up, secondary prevention could be improved in women, which might further reduce event rates.
Subject(s)
Cardiovascular Diseases/prevention & control , Healthcare Disparities , Peripheral Arterial Disease/drug therapy , Thrombosis/drug therapy , Aged , Antihypertensive Agents/therapeutic use , Asymptomatic Diseases , Cardiovascular Diseases/etiology , Cardiovascular Diseases/mortality , Chi-Square Distribution , Drug Therapy, Combination , Europe/epidemiology , Female , Fibrinolytic Agents/therapeutic use , Humans , Hypoglycemic Agents/therapeutic use , Hypolipidemic Agents/therapeutic use , Logistic Models , Male , Middle Aged , Odds Ratio , Peripheral Arterial Disease/complications , Peripheral Arterial Disease/mortality , Prospective Studies , Registries , Risk Assessment , Risk Factors , Sex Factors , Thrombosis/complications , Thrombosis/mortality , Time Factors , Treatment OutcomeABSTRACT
Cardiovascular event rates have been shown to increase substantially with the number of symptomatic disease locations. We sought to assess the risk profile, management and subsequent event rates of polyvascular disease patients. Consecutive outpatients were assessed for atherosclerotic risk factors and medications in the REACH Registry. A total of 19,117 symptomatic patients in Europe completed a 2-year follow-up: 77.2% with single arterial bed disease (coronary artery or cerebrovascular or peripheral arterial disease) and 22.8% with polyvascular disease (>/= 1 disease location). Polyvascular disease patients were older (68.5 +/- 9.4 vs 66.3 +/- 9.9 years, p < 0.0001), more often current or former smokers (64.9% vs 58.7%, p < 0.0001), and more often suffered from hypertension (59.5% vs 46.6%, p < 0.0001) and diabetes (34.5% vs 25.9%, p < 0.0001) than single arterial bed disease patients. Despite more intense medical therapy, risk factors (smoking, hypertension, low fasting glucose, and low fasting total cholesterol) were less often controlled in polyvascular disease patients. This was associated with substantially more events over 2 years compared with single arterial bed disease patients (cMACCE [cardiovascular death/non-fatal stroke/non-fatal MI] odds ratio, 1.63 [95% CI, 1.45-1.83], p < 0.0001). In conclusion, polyvascular disease patients have more cardiovascular risk factors, and the prognosis for these patients is significantly worse than for patients with single arterial bed disease. This suggests a need to improve detection and consequent medical treatment of polyvascular disease.
Subject(s)
Registries/statistics & numerical data , Severity of Illness Index , Vascular Diseases/epidemiology , Aged , Atherosclerosis/epidemiology , Comorbidity , Coronary Artery Disease/epidemiology , Europe/epidemiology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Peripheral Vascular Diseases/epidemiology , Risk Factors , Thrombosis/epidemiologyABSTRACT
AIMS: The European cardiac resynchronization therapy (CRT) survey is a joint initiative taken by the Heart Failure Association and the European Heart Rhythm Association of the European Society of Cardiology. The primary aim of this survey is to describe current European practice associated with CRT implantations. METHODS AND RESULTS: A total of 140 centres from 13 European countries contributed data from consecutive patients successfully implanted with a CRT device with or without an ICD between November 2008 and June 2009. The total number of patients enrolled was 2438. The median age of the patients was 70 years (IQR 62-76) and 31% were > or =75 years. It was found that 78% were in NYHA functional class III or IV and 22% in I or II. The mean ejection fraction was 27% +/- 8 and the mean QRS duration 157 ms +/- 32. The QRS duration was <120 ms in 9%. Atrial fibrillation was reported in 23%. It was found that 26% of patients had a previously implanted permanent pacemaker or ICD; 76% of procedures were performed by an electrophysiologist; 82% had an elective admission for implantation and the median duration of hospitalization was 3 days (IQR 2-7); and 73% received a CRT-D device which was more often implanted in men, younger patients, and with ischaemic aetiology. The mean QRS duration was reduced to 133 ms +/- 27 (P < 0.0001) at discharge. Peri-procedural complication rates were comparable to the rates reported in randomized trials. CONCLUSION: This CRT survey provides important information describing current European practice with regard to patient demographics, selection criteria, procedural routines, and status at discharge. These data should be useful for benchmarking individual patient management and national practice against wider experience.
Subject(s)
Cardiac Pacing, Artificial , Heart Failure/therapy , Aged , Aged, 80 and over , Female , Health Care Surveys , Heart Failure/etiology , Hospitalization , Humans , Male , Middle Aged , Myocardial Ischemia/complications , Pacemaker, Artificial , Prosthesis Design , Randomized Controlled Trials as TopicABSTRACT
AIMS: Peripheral arterial disease (PAD) and coronary artery disease (CAD) are manifestations of the same underlying condition, atherothrombosis. We compared patients with PAD only with those having PAD and concomitant documented CAD in terms of characteristics, risk factors, treatment and prognosis. METHODS AND RESULTS: This is a subgroup analysis of the German cohort of the Reduction of Atherothrombosis for Continued Health (REACH) Registry. It includes 483 patients with PAD only, and 479 patients with PAD plus CAD. Patients with concomitant cerebrovascular disease were excluded. Symptomatic PAD was defined as intermittent claudication (IC), confirmed by ankle brachial index <0.9, or PAD-related intervention. Patients in the total cohort were predominantly elderly (mean age 67.3 +/- 8.9 years), males (72.3%), current or previous smokers (80.18%), and had often abdominal obesity (49.6%). Atherosclerotic risk factors and comorbidities were highly prevalent. Patients with PAD + CAD compared to those with PAD only were significantly more intensively treated with regards to antihrombotic agents (97.1% vs. 88.8%), statins (80.2% vs. 51.6%), or ACE inhibitors/ARB (75.6% vs. 61.1%). After two-year follow-up, no significant differences between subgroups were noted for total mortality (4.6% vs. 5.5%), cardiovascular mortality (3.7% vs. 3.9%), non-fatal myocardial infarction (1.9% vs. 2.7%) but for non-fatal stroke (4.4% vs. 2.0%, P < 0.05). CONCLUSION: Peripheral arterial disease patients carry a high burden of risk factors and co-morbidities, and are at high risk of death and cardiovascular events. If documented CAD is absent, PAD patients are undertreated. Thus, in PAD patients, secondary cardiovascular prevention with stringent treatment of risk factors to the same extent as in CAD patients is mandatory, in line with current guidelines.
Subject(s)
Cardiovascular Diseases/prevention & control , Coronary Artery Disease/complications , Peripheral Vascular Diseases/physiopathology , Aged , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Cardiovascular Diseases/mortality , Coronary Artery Disease/physiopathology , Female , Fibrinolytic Agents/therapeutic use , Follow-Up Studies , Germany/epidemiology , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Intermittent Claudication/drug therapy , Intermittent Claudication/etiology , Intermittent Claudication/physiopathology , Male , Middle Aged , Peripheral Vascular Diseases/drug therapy , Peripheral Vascular Diseases/etiology , Practice Guidelines as Topic , Prognosis , Prospective Studies , Registries , Risk FactorsABSTRACT
AIMS: The aim of this study was to describe the characteristics of patients with atrial fibrillation (AF) enrolled in the Central Registry of the German Competence NETwork on Atrial Fibrillation (AFNET) and to assess current medical practice in patients treated at various levels of medical care in Germany. METHODS AND RESULTS: From February 2004 to March 2006, 9582 ambulatory and hospitalized patients with ECG-documented AF were enrolled by 194 participating study centres from all levels of medical care in Germany. Clinical type of AF was reported as paroxysmal in 2893, persistent in 1873, and permanent in 3134 patients or classified as a first episode in 1035 patients. Predisposing conditions were common and present in 87.6% of the patients. Most patients were symptomatic with AF (75.1%). Rhythm control in persistent AF was provided to 53.4% of the symptomatic patients and to 47.8% of the patients without symptoms. Anticoagulation for stroke prevention was given to 71.4% of the patients considered eligible by applicable guidelines and to 48.4% of patients with low risk where guidelines do not recommend anticoagulation. CONCLUSION: This registry provides insight into current medical care of patients with AF in Germany. The use of oral anticoagulation in eligible patients was among the highest reported, whereas decisions on rate and rhythm control often do not follow current recommendations.
Subject(s)
Atrial Fibrillation/epidemiology , Atrial Fibrillation/therapy , Guideline Adherence/trends , Registries/statistics & numerical data , Ablation Techniques , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Arrhythmia Agents/therapeutic use , Anticoagulants/therapeutic use , Atrial Fibrillation/complications , Echocardiography , Electric Countershock/methods , Female , Germany/epidemiology , Humans , Hypertension/complications , Male , Middle Aged , Risk Factors , Stroke/prevention & control , Young AdultABSTRACT
The differential allocation hypothesis predicts that parents should adjust their current investment in relation to perceived mate attractiveness if this affects offspring fitness. It should be selectively advantageous to risk more of their future reproductive success by investing heavily in current offspring of high reproductive value but to decrease investment if offspring value is low. If the benefits of mate attractiveness are limited to a particular offspring sex we would instead expect relative investment in male versus female offspring to vary with mate attractiveness, referred to as 'differential sex allocation'. We present strong evidence for differential allocation of parental feeding effort in the wild and show an immediate effect on a component of offspring fitness. By experimentally reducing male UV crown coloration, a trait known to indicate attractiveness and viability in wild-breeding blue tits (Parus caeruleus), we show that females, but not males, reduce parental feeding rates and that this reduces the skeletal growth of offspring. However, differential sex allocation does not occur. We conclude that blue tit females use male UV coloration as an indicator of expected offspring fitness and adjust their investment accordingly.